Attovia Therapeutics adds James Topper as director

Attovia Therapeutics, Inc. filed an initial beneficial ownership statement for James N. Topper, who is identified as a director of the company.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. filed an initial beneficial ownership statement for James N. Topper, who is identified as a director of the company. The filing does not list any equity transactions or derivative positions for him. An accompanying exhibit provides a Power of Attorney authorizing certain filing-related actions.

Key Terms

beneficial ownership, derivative positions, Power of Attorney

3 terms

beneficial ownership financial

"filed an initial beneficial ownership statement for James N. Topper"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

derivative positions financial

"does not list any equity transactions or derivative positions"

Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.

Power of Attorney regulatory

"An accompanying exhibit provides a Power of Attorney authorizing"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for ATTO and James N. Topper indicate?

The filing identifies James N. Topper as a director of Attovia Therapeutics, Inc. It reports no equity transactions or derivative positions and includes a Power of Attorney as an exhibit.

Were any Attovia Therapeutics (ATTO) shares bought or sold by James N. Topper in this filing?

No. The insider data for this Form 3 shows no reported purchases or sales of Attovia Therapeutics, Inc. securities by James N. Topper and no derivative transactions.

Does James N. Topper hold any reported derivative securities of ATTO in this Form 3?

No derivative holdings are listed. The derivativeSummary is empty and the data show no derivative transactions, so no options or similar instruments are reported here for James N. Topper.

What is the purpose of the Power of Attorney mentioned in the ATTO Form 3?

The remarks reference an exhibit titled Power of Attorney. This typically authorizes designated individuals to sign and submit beneficial ownership reports on the insider’s behalf for Attovia Therapeutics, Inc.

Is James N. Topper reported as a 10% owner of Attovia Therapeutics (ATTO)?

No. The reporting-person information classifies James N. Topper as a director and indicates he is not a ten percent owner of Attovia Therapeutics, Inc. in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 09:26 AM Accepted by SEC EDGAR 08/04/2026 - 07:30 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Topper James N

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit Index Exhibit No. EX-24.1 Description Power of Attorney

No securities are beneficially owned.

	/s/ Steven Chan, Attorney-in-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)